Skip to content
All news
Analysis

TD Cowen Upgrades Starbucks to Buy, Raises Target to $120

TD Cowen upgraded Starbucks from Hold to Buy and raised its price target to $120, citing numerous tangible drivers for margin recovery and sales growth.

May 14, 2026
2 min read
Source: 24/7 Wall St.
Share:

Key Numbers

previous rating
Hold
new rating
Buy
old price target
$106
new price target
$120
upside
13.2%

TD Cowen upgraded Starbucks (NASDAQ:SBUX) from Hold to Buy and raised its price target to $120 from $106, citing "numerous tangible drivers" for a comeback story.

Rating Change

  • Previous Rating: Hold
  • New Rating: Buy
  • Previous Price Target: $106
  • New Price Target: $120 (implies ~13.2% upside)

Analyst Rationale

TD Cowen analysts pointed to several tangible drivers that should fuel positive sales revisions against a strong category backdrop:

  • Margin Recovery: Improved operational efficiency and supply chain management.
  • Sales Drivers: Menu innovation, international expansion, and rising demand for cold beverages.
  • Strong Category Backdrop: Robust performance in the restaurant and beverage sector.

Context

Starbucks shares have been volatile over the past year amid inflationary pressures and supply chain challenges. However, recent quarterly results showed signs of improvement, leading to this upgrade. No other major analysts have echoed this view yet, but the upgrade signals growing confidence in Starbucks' ability to reignite growth.

What to Make of It

TD Cowen's upgrade reflects a positive outlook for Starbucks, but investors should consider that the new price target is still subject to economic risks and competition. Monitor upcoming quarterly reports to assess whether the growth drivers materialize.

Frequently Asked Questions

TD Cowen upgraded Starbucks from Hold to Buy with a $120 price target.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.